학술논문
Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination.
Document Type
Article
Author
Arance, Ana; de la Cruz-Merino, Luis; Petrella, Teresa M.; Jamal, Rahima; Ny, Lars; Carneiro, Ana; Berrocal, Alfonso; Márquez-Rodas, Ivan; Spreafico, Anna; Atkinson, Victoria; Costa Svedman, Fernanda; Mant, Andrew; Khattak, Muhammad A.; Mihalcioiu, Catalin; Jang, Sekwon; Cowey, C. Lance; Smith, Alan D.; Hawk, Natalyn; Chen, Ke; Diede, Scott J.
Source
Journal of Clinical Oncology; Jan2023, Vol. 41 Issue 1, p75-85, 11p
Subject
Language
ISSN
0732183X